Michael A. O’Donnell

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety et al. · The Lancet Oncology · 2020 · 442 citations · Full text

Medicine, Oncology, Urology +13

Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice

Hamid Rabb, Frank Daniels, Michael A. O’Donnell et al. · American Journal of Physiology-Renal Physiology · 2000 · 353 citations

Medicine, Immunology, Pathology +17

Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose

Rosario V. Freeman, Michael A. O’Donnell, David Share et al. · The American Journal of Cardiology · 2002 · 337 citations

Medicine, Cardiology, Nephrology +16

Extent of Pelvic Lymphadenectomy and Its Impact On Outcome in Patients Diagnosed With Bladder Cancer: Analysis of Data From the Surveillance, Epidemiology and End Results Program Data Base

Badrinath R. Konety, Sue A. Joslyn, Michael A. O’Donnell · The Journal of Urology · 2003 · 329 citations

Medicine, Oncology, Surgery +9

Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer☆

Fadi N. Joudi, Michael A. O’Donnell · Urologic Oncology Seminars and Original Investigations · 2006 · 243 citations

Medicine, Pharmacotherapy, Urology +7